BACKGROUND: Concerns exist that women are underrepresented in trials of cardiovascular medications. OBJECTIVES: The authors sought to examine women's participation and the reported safety and efficacy by gender for pivotal cardiovascular disease (CVD) trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications. METHODS: On the basis of publicly available FDA reviews, the authors assessed enrollment of women in trials supporting 36 drug approvals from 2005 to 2015. Prevalence-corrected estimates for the participation of women were calculated as the percentage of women among trial participants divided by the percentage of women in the disease population (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting similar representation of women in the trial and disease population. Sex differences in efficacy and safety were assessed. RESULTS: The proportion of women enrolled ranged from 22% to 81% (mean 46%). The calculated PPR by disease area was within or above the desirable range for atrial fibrillation (0.8 to 1.1), hypertension (0.9), and pulmonary arterial hypertension (1.4); PPR was <0.8 for heart failure (0.5 to 0.6), coronary artery disease (0.6), and acute coronary syndrome/myocardial infarction (0.6). The authors found little indication of clinically meaningful gender differences in efficacy or safety. Gender differences in efficacy or safety were described in labeling for 4 drugs. CONCLUSIONS: Women were well represented in trials of drugs for hypertension and atrial fibrillation, and overrepresented for pulmonary arterial hypertension. Representation of women fell below a PPR of 0.8 for trials in heart failure, coronary artery disease, and acute coronary syndrome. Minimal gender differences in drug efficacy and safety profiles were observed. Published by Elsevier Inc.
BACKGROUND: Concerns exist that women are underrepresented in trials of cardiovascular medications. OBJECTIVES: The authors sought to examine women's participation and the reported safety and efficacy by gender for pivotal cardiovascular disease (CVD) trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications. METHODS: On the basis of publicly available FDA reviews, the authors assessed enrollment of women in trials supporting 36 drug approvals from 2005 to 2015. Prevalence-corrected estimates for the participation of women were calculated as the percentage of women among trial participants divided by the percentage of women in the disease population (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting similar representation of women in the trial and disease population. Sex differences in efficacy and safety were assessed. RESULTS: The proportion of women enrolled ranged from 22% to 81% (mean 46%). The calculated PPR by disease area was within or above the desirable range for atrial fibrillation (0.8 to 1.1), hypertension (0.9), and pulmonary arterial hypertension (1.4); PPR was <0.8 for heart failure (0.5 to 0.6), coronary artery disease (0.6), and acute coronary syndrome/myocardial infarction (0.6). The authors found little indication of clinically meaningful gender differences in efficacy or safety. Gender differences in efficacy or safety were described in labeling for 4 drugs. CONCLUSIONS:Women were well represented in trials of drugs for hypertension and atrial fibrillation, and overrepresented for pulmonary arterial hypertension. Representation of women fell below a PPR of 0.8 for trials in heart failure, coronary artery disease, and acute coronary syndrome. Minimal gender differences in drug efficacy and safety profiles were observed. Published by Elsevier Inc.
Entities:
Keywords:
Food and Drug Administration; cardiovascular diseases/therapy; clinical trials; drug efficacy; drug safety; women’s health
Authors: Matthew E Arnegard; Lori A Whitten; Chyren Hunter; Janine Austin Clayton Journal: J Womens Health (Larchmt) Date: 2020-01-22 Impact factor: 2.681
Authors: Gennaro Giustino; Jessica Overbey; Doris Taylor; Gorav Ailawadi; Katherine Kirkwood; Joseph DeRose; Marc A Gillinov; François Dagenais; Mary-Lou Mayer; Alan Moskowitz; Emilia Bagiella; Marissa Miller; Paul Grayburn; Peter K Smith; Annetine Gelijns; Patrick O'Gara; Michael Acker; Anuradha Lala; Judy Hung Journal: JACC Heart Fail Date: 2019-06 Impact factor: 12.035
Authors: Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison Journal: J Am Coll Cardiol Date: 2020-02-18 Impact factor: 24.094
Authors: Vaishnavi Kannan; Kathleen E Wilkinson; Mereeja Varghese; Sarah Lynch-Medick; Duwayne L Willett; Teresa A Bosler; Ling Chu; Samantha I Gates; M E Blair Holbein; Mallory M Willett; Sharon C Reimold; Robert D Toto Journal: J Am Med Inform Assoc Date: 2019-08-01 Impact factor: 4.497